856 related articles for article (PubMed ID: 9041202)
41. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Giatromanolaki A; Koukourakis MI; Sivridis E; O'Byrne K; Cox G; Thorpe PE; Gatter KC; Harris AL
Clin Cancer Res; 2000 May; 6(5):1917-21. PubMed ID: 10815916
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
[TBL] [Abstract][Full Text] [Related]
43. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
Fujiwara M; Muragaki Y; Ooshima A
Arch Dermatol Res; 2005 Oct; 297(4):161-9. PubMed ID: 16184401
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Ann Diagn Pathol; 2003 Feb; 7(1):1-8. PubMed ID: 12616467
[TBL] [Abstract][Full Text] [Related]
45. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
46. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Fukuda S; Shirahama T; Imazono Y; Tsushima T; Ohmori H; Kayajima T; Take S; Nishiyama K; Yonezawa S; Akiba S; Akiyama S; Ohi Y
Cancer; 1999 Mar; 85(6):1323-30. PubMed ID: 10189138
[TBL] [Abstract][Full Text] [Related]
47. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study.
Sipos B; Weber D; Ungefroren H; Kalthoff H; Zühlsdorff A; Luther C; Török V; Klöppel G
Int J Cancer; 2002 Dec; 102(6):592-600. PubMed ID: 12448000
[TBL] [Abstract][Full Text] [Related]
48. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport.
Ozawa K; Kondo T; Hori O; Kitao Y; Stern DM; Eisenmenger W; Ogawa S; Ohshima T
J Clin Invest; 2001 Jul; 108(1):41-50. PubMed ID: 11435456
[TBL] [Abstract][Full Text] [Related]
49. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression.
Deroanne CF; Hajitou A; Calberg-Bacq CM; Nusgens BV; Lapière CM
Cancer Res; 1997 Dec; 57(24):5590-7. PubMed ID: 9407972
[TBL] [Abstract][Full Text] [Related]
50. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM; Camps C; Sirera R
Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
[TBL] [Abstract][Full Text] [Related]
51. [Angiogenic factors in endometriosis].
Fujimoto J; Tamaya T
Nihon Rinsho; 2001 Jan; 59 Suppl 1():65-9. PubMed ID: 11235180
[No Abstract] [Full Text] [Related]
52. Clinical significance of the determination of angiogenic factors.
Toi M; Taniguchi T; Yamamoto Y; Kurisaki T; Suzuki H; Tominaga T
Eur J Cancer; 1996 Dec; 32A(14):2513-9. PubMed ID: 9059341
[No Abstract] [Full Text] [Related]
53. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis.
Chang J; Most D; Bresnick S; Mehrara B; Steinbrech DS; Reinisch J; Longaker MT; Turk AE
Plast Reconstr Surg; 1999 Jan; 103(1):1-9; discussion 10. PubMed ID: 9915157
[TBL] [Abstract][Full Text] [Related]
54. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
55. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Sivridis E; Giatromanolaki A; Gatter KC; Harris AL; Koukourakis MI;
Cancer; 2002 Sep; 95(5):1055-63. PubMed ID: 12209691
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.
McCabe CJ; Boelaert K; Tannahill LA; Heaney AP; Stratford AL; Khaira JS; Hussain S; Sheppard MC; Franklyn JA; Gittoes NJ
J Clin Endocrinol Metab; 2002 Sep; 87(9):4238-44. PubMed ID: 12213878
[TBL] [Abstract][Full Text] [Related]
58. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
59. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
[TBL] [Abstract][Full Text] [Related]
60. Investigating the role of angiogenesis in systemic lupus erythematosus.
Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
